UroActive电子人工尿道括约肌治疗男性压力性尿失禁的首例人体评估
这项前瞻性、多中心、单臂、首例人体研究纳入6例保守或手术治疗无效的男性压力性尿失禁患者,评估UroActive装置激活后第一年的可行性、安全性和有效性。所有患者植入和激活成功,365天内无翻修或取出,尿垫重量均减少≥50%,生活质量显著改善,无意外严重不良事件。
要点
- 6例男性压力性尿失禁患者植入UroActive电子人工尿道括约肌均成功激活。
- 激活后365天无翻修或取出,尿垫重量减少≥50%者100%、≥75%者83.3%。
- 生活质量评分显著改善,无意外严重不良事件,需更大样本长期随访验证。
核心结论
- UroActive装置在男性压力性尿失禁患者激活后365天内显示出有前景的可行性、安全性和功能结局。
- 患者症状显著改善且满意度高,无手术翻修。
研究设计与样本
- 前瞻性、多中心、单臂、首例人体研究,纳入6例保守或手术治疗无效的男性压力性尿失禁患者。
- 植入UroActive后计划随访5年(激活后),评估激活成功率、翻修和取出率等终点。
主要发现
- 所有6例患者植入和装置激活成功(100%)。
- 激活后365天内无取出或翻修。
- 激活后365天,所有患者尿垫重量减少≥50%,5例(83.3%)减少≥75%。
- 每日尿垫使用中位数从3.7片降至1.0片。
- 尿流率保持在可接受范围,残余尿量极少;所有生活质量量表评分显著改善。
关键数值与推荐
- 激活后365天尿垫重量减少≥50%:6/6例(100%)。
- 激活后365天尿垫重量减少≥75%:5/6例(83.3%)。
- 每日尿垫使用中位数从3.7片降至1.0片。
临床怎么用
- 对于保守或手术治疗无效的男性压力性尿失禁患者,UroActive装置可能是一种可行的新选择。
- 需关注装置缺陷(主要涉及遥控器),但无意外严重不良事件。
局限性
- 样本量小(6例),随访时间短(激活后365天),需更大规模及长期随访研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the feasibility, safety, and efficacy during the first year of use of the UroActive device in male patients with stress urinary incontinence. MATERIALS AND METHODS: This prospective, multicenter, single-arm, first-in-human study enrolled 6 male patients with bothersome stress urinary incontinence unresponsive to conservative or surgical treatments. After UroActive implantation, follow-up was planned for 5 years (postactivation). Study end points included successful device activation, revision, and explantation rates. Other end points assessed 24 hours pad-weight test reduction, pad usage, uroflowmetry, postvoid residual urine, and patient-reported outcomes (International Consultation Incontinence Questionnaires UI Short Form, EQ-5D, I-QOL, Urinary Symptom Profile). Adverse events were collected throughout the study. RESULTS: All 6 patients underwent successful implantation and device activation (100%). No explants or revisions were required during the 365 days postactivation. At 365 days postactivation, the pad weight was reduced by ≥ 50% in all patients and reduced by ≥ 75% in 5 (83.3%). The median pad use decreased from 3.7 to 1.0 pad per day. Uroflowmetry remained within acceptable ranges, and postvoid residual urine was minimal. Quality of life scores significantly improved across all instruments. Nine device deficiencies were reported, all involving the patient remote control. No unanticipated serious adverse events occurred. CONCLUSIONS: In men with stress urinary incontinence, the UroActive device demonstrates promising feasibility, safety, and functional outcomes during the 365 days postactivation. Patients experienced substantial symptom improvement and high satisfaction, with no surgical revisions. Larger studies with extended follow-up are needed to confirm these findings and assess long-term device performance.
引用
- Mozer P, Beaugerie A, Perrouin-Verbe MA, et al. First-In-Human Assessment of the UroActive Electronic Artificial Urinary Sphincter for Treating Male Patients with Stress Urinary Incontinence. J Urol. 2026. PMID: 41564274. doi:10.1097/JU.0000000000004945
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。